Liquidia Technologies Inc (LQDA)

Currency in USD
26.840
-0.460(-1.68%)
Closed·
26.930+0.090(+0.34%)
·
LQDA Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
LQDA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
26.16527.690
52 wk Range
8.75028.000
Key Statistics
Prev. Close
27.3
Open
27.3
Day's Range
26.165-27.69
52 wk Range
8.75-28
Volume
2.6M
Average Volume (3m)
2.83M
1-Year Change
178.71%
Book Value / Share
0.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LQDA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
36.667
Upside
+36.61%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Liquidia Technologies Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Liquidia Technologies Inc Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Employees
170

Liquidia Technologies Inc Earnings Call Summary for Q2/2025

  • Q2 revenue surged to $8.8M, beating forecasts by 125.51%, driven by strong Eutropia sales; stock jumped 16.04% pre-market to $24.60
  • EPS missed at -$0.49 vs -$0.42 forecast; company maintains $173M cash cushion and plans manufacturing expansion by 2026
  • Over 900 unique Eutropia prescriptions; management expects continued growth in prescriber base and improved payer landscape
  • Analysts project 202% revenue growth for FY2025; maintain strong Buy consensus despite potential patent litigation risks
  • CEO emphasized rapid market entry and strong initial demand; CFO stressed commitment to patient choice for Eutropia
Last Updated: 12/08/2025, 14:18
Read Full Transcript

Compare LQDA to Peers and Sector

Metrics to compare
LQDA
Peers
Sector
Relationship
P/E Ratio
−15.2x−2.9x−0.6x
PEG Ratio
0.590.200.00
Price/Book
152.1x2.5x2.6x
Price / LTM Sales
119.6x1.7x3.3x
Upside (Analyst Target)
34.1%110.8%37.9%
Fair Value Upside
Unlock12.5%3.7%Unlock

Analyst Ratings

8 Buy
0 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 36.667
(+36.61% Upside)

Earnings

Latest Release
Aug 12, 2025
EPS / Forecast
-0.49 / -0.42
Revenue / Forecast
8.84M / 3.92M
EPS Revisions
Last 90 days

LQDA Income Statement

People Also Watch

179.09
ALAB
+0.88%
36.36
YOU
+4.72%
16.80
OSCR
+8.95%
47.070
ASTS
+4.65%
15.540
QBTS
+4.93%

FAQ

What Stock Exchange Does Liquidia Technologies Trade On?

Liquidia Technologies is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Liquidia Technologies?

The stock symbol for Liquidia Technologies is "LQDA."

What Is the Liquidia Technologies Market Cap?

As of today, Liquidia Technologies market cap is 2.30B.

What Is Liquidia Technologies's Earnings Per Share (TTM)?

The Liquidia Technologies EPS (TTM) is -1.82.

When Is the Next Liquidia Technologies Earnings Date?

Liquidia Technologies will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is LQDA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Liquidia Technologies Stock Split?

Liquidia Technologies has split 0 times.

How Many Employees Does Liquidia Technologies Have?

Liquidia Technologies has 170 employees.

What is the current trading status of Liquidia Technologies (LQDA)?

As of 23 Aug 2025, Liquidia Technologies (LQDA) is trading at a price of 26.84, with a previous close of 27.30. The stock has fluctuated within a day range of 26.17 to 27.69, while its 52-week range spans from 8.75 to 28.00.

What Is Liquidia Technologies (LQDA) Price Target According to Analysts?

The average 12-month price target for Liquidia Technologies is USD36.66667, with a high estimate of USD54 and a low estimate of USD6. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +36.61% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.